Nuplazid More Effective in Reducing Severe Psychosis in Alzheimer’s, Trial Shows

Nuplazid More Effective in Reducing Severe Psychosis in Alzheimer’s, Trial Shows
Nuplazid (pimavanserin) is more effective in reducing severe psychotic symptoms — particularly hallucinations and delusions — in Alzheimer’s disease patients than in those with milder symptoms, according to additional Phase 2 clinical trial results. The study, “Pimavanserin in Alzheimer’s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms,” was published in The Journal of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

4 comments

Leave a Comment

Your email address will not be published. Required fields are marked *